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Summary
Background Epidemiological studies indicate that gene–environment interactions
play a role in atopic dermatitis (AD).
Objectives To review the evidence for gene–environment interactions in AD aetiol-
ogy, focusing on filaggrin (FLG) loss-of-function mutations.
Methods A systematic search from inception to September 2018 in Embase, MED-
LINE and BIOSIS was performed. Search terms included all synonyms for AD and
filaggrin/FLG; any genetic or epidemiological study design using any statistical
methods were included. Quality assessment using criteria modified from guid-
ance (ROBINS-I and Human Genome Epidemiology Network) for nonrandom-
ized and genetic studies was completed, including consideration of power.
Heterogeneity of study design and analyses precluded the use of meta-analysis.
Results Of 1817 papers identified, 12 studies fulfilled the inclusion criteria
required and performed formal interaction testing. There was some evidence for
FLG–environment interactions in six of the studies (P-value for interaction
≤ 005), including early-life cat ownership, older siblings, water hardness, phtha-
late exposure, higher urinary phthalate metabolite levels (which all increased AD
risk additional to FLG null genotype) and prolonged breastfeeding (which
decreased AD risk in the context of FLG null genotype). Major limitations of pub-
lished studies were the low numbers of individuals (ranging from five to 94)
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with AD and FLG loss-of-function mutations and exposure to specific environ-
mental factors, and variation in exposure definitions.
Conclusions Evidence on FLG–environment interactions in AD aetiology is limited.
However, many of the studies lacked large enough sample sizes to assess these
interactions fully. Further research is needed with larger sample sizes and clearly
defined exposure assessment.
What’s already known about this topic?
• Gene–environment interactions are considered important in the aetiology of atopic
dermatitis.
• Loss-of-function mutations in the gene coding filaggrin (FLG) are the most consis-
tently reported genetic variants for atopic dermatitis.
• Studies have reported evidence for gene–environment interaction involving FLG
and a range of different environmental exposures.
What does this study add?
• There is some evidence for FLG–environment interactions in the aetiology of atopic
dermatitis; however, the evidence is limited.
• Studies lack large enough sample sizes to achieve adequate power in order to assess
these interactions fully.
Atopic dermatitis (AD), also known as eczema or atopic
eczema, is a complex, multifactorial, often debilitating dis-
ease.1 The prevalence of AD has risen rapidly, suggesting that
environmental factors might be responsible for such changes.2
It is estimated that up to 20% of children and 3% of adults in
high-income countries are affected by AD.3 In order to dis-
cover ways to reduce the personal and public health burden,
it is necessary to gain a better understanding of the aetiology
of AD.
Considerable phenotypic heterogeneity, evidence for multi-
ple genetic risk mechanisms4 and incomplete penetrance have
led to complexities in understanding the genetic basis of AD.5
There have been 31 risk loci identified for AD to date.4 Loss-
of-function mutations in the gene encoding filaggrin (FLG) are
the strongest and most significantly associated genetic variants
for AD.6
Profilaggrin is an insoluble protein found in the outer epi-
dermis; monomeric filaggrin has multiple functions including
aggregation of keratin filaments.7 FLG is essential for normal
epidermal barrier function and formation,8 contributing to the
skin water-holding capacity and pH balance.9 The two most
prevalent loss-of-function mutations in FLG in white European
populations are R510X and 2282del4, present in approxi-
mately 9% of healthy people in Northern European popula-
tions. These mutations are strongly associated with AD risk,
particularly early-onset and severe disease.6 Other, less preva-
lent, loss-of-function mutations in FLG have been identi-
fied.10–12 Despite increased understanding of the importance
of genetic factors, the rising AD prevalence has been too
substantial and rapid to be explained purely by genetic fac-
tors.13 Environmental factors have been implicated in the ris-
ing AD prevalence; exposure to such factors in utero or in later
life may play a role in AD aetiology.14
Gene–environment interaction (GEI) may be defined as
occurring when individuals with different genotypes respond
to an environmental exposure in different ways; this interac-
tion contributes to many common phenotypes and complex
genetic traits. There is evidence that GEI plays a role in atopic
diseases, such as asthma, in which genotype interacts with
environmental factors, including maternal smoking and house
dust mite.15,16 A recent review on allergic diseases highlighted
that several studies exploring GEI in AD exist, yet findings
have not been synthesized (e.g. in a systematic review).17 Our
objective was to perform a systematic review of the evidence
for GEI in AD, focusing on interactions with the FLG null
genotype, because this is the strongest and most widely repli-
cated AD genetic risk factor, and because the role of filaggrin
in skin barrier function provides a priori support for a hypo-
thetical GEI effect.
Materials and methods
This systematic review was prospectively registered (PROS-
PERO ID CRD42017057818). A detailed electronic search of
MEDLINE and Embase via Ovid, and BIOSIS via Web of
Science was undertaken from inception of each database to
September 2018, identifying manuscripts in any language. To
define AD, the search terms ‘atopic dermatitis’, ‘atopic
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eczema’ and ‘eczema’ were used, and to define FLG mutations,
‘filaggrin’, ‘FLG’, possible misspellings and previously reported
FLG mutation names were included in the strategy (Methods
S1; see Supporting Information). We focused on incident AD
cases, including studies that examined interactions for AD
development rather than interactions for established AD. To
avoid defining an exhaustive list of environmental factors a
priori, the inclusion of any environmental factor was assessed
during the title and abstract screening. We defined environ-
mental exposures as proposed by Rothman.18 The primary
outcome measure was evidence of a statistically significant
(defined as P < 005) FLG–environment interaction in the aeti-
ology of AD and the secondary outcome was the strength of
the association of the interaction (evidence of a dose–response
relationship) and AD severity. Details of abstract screening,
inclusion and exclusion criteria and data extraction are pro-
vided in Methods S2 and Table S1 (see Supporting Informa-
tion).
Quality and bias assessment was performed using criteria
modified from guidance for nonrandomized studies to deter-
mine quality of studies; ROBINS-I to assess risk of bias in
nonrandomized studies of interventions, and HuGENet for
genetic studies, including assessing whether confounders were
considered.19,20 These two tools were combined to determine
bias in genetic and environmental studies, as neither tool was
designed for GEI studies.
Post hoc sample-size calculations were undertaken to esti-
mate the sample size required to detect a GEI effect varying
between 12 and 26 in a case–control/cohort study for a bin-
ary single-nucleotide polymorphism (SNP) and binary expo-
sure under a series of assumptions for model parameters
(Table S2; see Supporting Information), using R 350 (R pack-
age powerGWASinteraction).
Results
The search identified 1817 papers of possible relevance
(Fig. 1); 12 met our inclusion criteria (Table S1; see Support-
ing Information). Papers tested various environmental expo-
sures (Table 1).
The study designs of these 12 papers included 10 cohort
studies, one case–control study and one family-based study
(Table S3; see Supporting Information). Study populations
ranged from 296 to 5188 individuals and participant ages ran-
ged from 1 month to 69 years. The number of participants in
each study with FLG loss-of-function mutations ranged from
27 (91%) to 459 (102%). The AD definition and method of
ascertainment varied between studies (Table S4; see Support-
ing Information).21–23 None of the included studies investi-
gated the strength of interaction or AD severity.
Of the 12 publications, including 15 studies (Table S4; see
Supporting Information), six studies showed evidence for GEI
(P < 005) (Table 1). Most studies used regression models to
calculate P-values and some presented hazard ratios (HRs).
Heterogeneity in study design and exposures precluded formal
meta-analysis.
Cat exposure
Two studies assessed the FLG–cat interaction.24,25 Bisgaard et al.
tested for an interaction in the Copenhagen Prospective Study
on Asthma in Childhood (COPSAC) (n = 379) and reported an
increased risk related to cat exposure at birth among children
aged 0–5 years who had FLG null mutation [HR 1111, 95%
confidence interval (CI) 379–3260; Pinteraction = 00008]; find-
ings were replicated in the Manchester Asthma and Allergy
Study (MAAS) (n = 503), with an increased risk owing to inter-
action of cat exposure at birth and FLG null genotype (HR 382,
95% CI 135–1081; Pinteraction = 0011). Schuttelaar et al. (n =
934) reported no overall interaction (P = 085) between FLG
null genotype (one/two FLG loss-of-function mutations) and
cat exposure at home [odds ratio (OR) with FLG loss-of-func-
tion mutation(s) and cat exposure = 19; OR for FLG wild-type
individuals and cat exposure = 21]. However, Schuttelaar et al.
reported an interaction when examining the 2282del4 mutation
only (P = 0003), with a stronger effect in children aged 0–8
years with a cat at home (OR 60, 95% CI 32–113) compared
with those without (OR 22, 95% CI 14–37).25 All those with
2282del4 mutations were heterozygous.25 As all FLG loss-of-
function mutations have biological equivalence on filaggrin pro-
tein expression, there is no clear biological plausibility for an
interaction with one mutation and not another. Evidence for
GEI comes from small numbers of individuals with FLG muta-
tion, cat exposure and development of AD. In Bisgaard et al. five
such individuals were reported. Schuttelaar et al. did not provide
the number of individuals, but it can be inferred that n < 84 for
the overall interaction and n < 50 for the 2282del4 interac-
tion.24,25
Dog exposure
Bisgaard et al. tested for an interaction between FLG loss-of-
function mutations and dog ownership in the first year of life.
There was no evidence for an interaction in COPSAC (n =
379) (result statistics not reported) or MAAS (n = 503) (HR
059, 95% CI 016–220; P = 043).24
Siblings
One study reported an interaction between FLG genotype and
presence of older siblings among both children attending and
those not attending daycare at 2 years of age in two separate stud-
ies – LISAplus cohort (aged 6–72 months, n = 1037, interaction
OR 327, 95% CI 114–936; P < 005) and GINIplus cohort
(12–72 months, n = 1828, interaction OR 241, 95% CI 106–
548; P < 005).26 This interaction increased the risk of AD.27
Parity, maternal atopy and child’s sex
Henderson et al. found no evidence of an interaction between
FLG genotype with parity (n = 4463, P = 0802), maternal
asthma or AD (n = 5188, P = 0486 and P = 0884, respec-
tively) or the child’s sex (P = 0959)28 in children aged 6
© 2019 The Authors. British Journal of Dermatology
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months to 11 years who were part of a prospective cohort
study.
Maternal IgE sensitization
Esparza-Gordillo et al. conducted a parent-of-origin analysis
investigating the effect of a child’s FLG genotype and maternal
and paternal FLG genotypes on the child’s AD risk (n = 1209
families).29 Although interactions were not the focus of this
study, results were stratified by maternal IgE sensitization sta-
tus, allowing us to compare the effect of the child’s FLG geno-
type in those whose mothers were or were not IgE sensitized.
The child’s FLG genotype had a stronger risk effect when
mothers had normal IgE levels [relative risk (RR) for one FLG
loss-of-function mutation = 230 (95% CI 164–322); RR for
two FLG loss-of-function mutations = 719 (95% CI 377–
137)] compared with those who had sensitized mothers
[RR1 137 (95% CI 097–194); RR2 298 (95% CI 119–
745)]. However, CIs were wide and overlapping. Esparza-
Gordillo et al. reported the opposite for effect of maternal
genotype, so it is unclear whether this evidence points to a
true interaction with exposure to mothers with elevated IgE or
whether the observation results from maternal genetic effects
in utero or imprinting effects of FLG genotype.29
Smoking
One study tested for possible interactions with FLG mutations
and maternal smoking during pregnancy (n = 5140) or child-
hood environmental tobacco smoke exposure (n = 4874).
Their results showed no evidence for either interaction
43 full-text articles excluded for 
the following reasons: 
12 were conference 
proceedings or abstract only 
10 had no interaction testing 
5 were duplicates not identified 
above
6 had an outcome that was not 
atopic dermatitis
2 did not have a control group 
2 were literature reviews 
2 were letters 
2 included no environmental 
factors 
1 presented no statistical 
analysis results
1 is follow-on work informed by 
the preliminary findings of this 
systematic review   
1399 records identified 
through Embase via Ovid
1817 records screened by 
abstract 
55 full-text articles assessed 
for eligibility 
1762 records excluded - title 
and/or abstract not on review 
topic
1526 records identified 
through BIOSIS 
750 records identified 
through MEDLINE via Ovid
1858 duplicates removed 
12 papers included 
Fig 1. Flowchart showing systematic review.
Table 1 Environmental exposures assessed in included studies
Environmental exposures
assessed in one paper
Environmental
exposures assessed in
two or more papers
Older siblings and daycare
attendancea,27 sex,28
maternal parity,28 maternal
AD,28 maternal smoking,28
environmental tobacco
smoke exposure in early
life,28 birth year,31 serum
vitamin D levels,33 maternal
IgE sensitization29
Early-life cat exposurea,24,25
breastfeedinga,28,30 phthalate
exposure in urine metabolites
and household dusta,35,36
water hardnessa,26,37
aEnvironmental exposures where significant interactions with FLG
were reported (P < 005).
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(maternal smoking P = 0362, child environmental tobacco
smoke exposure P = 0742).23
Breastfeeding
Ziyab et al. found evidence for a protective association
between breastfeeding duration and AD in children aged 1 or
2 years (n = 885) carrying at least one FLG loss-of-function
mutation (P = 002), with no evidence in those without an
FLG null mutation (P = 064).30 However, this was a stratified
analysis and formal interaction testing was not undertaken.
Henderson et al. found no evidence for this interaction (P =
0952) in their earlier, larger study (n = 5158).28
Birth year
Thyssen et al. investigated FLG and year of birth in adults aged
18–69 years (n = 3202) but did not report any evidence of
interaction (P = 019) on AD risk.31
Water hardness
Interaction of FLG genotype and water hardness has been
investigated in two papers within the same cohort. Perkin et al.
investigated the association between calcium and chlorine
levels in water and AD during the first 3 months of life in the
Enquiring About Tolerance study, a U.K. population-based
cohort of 1303 infants. Interaction tests did not show a statis-
tically significant interaction between FLG genotype and high
calcium-low chlorine concentration in water, low calcium-
high chlorine or high calcium-high chlorine concentrations.26
They subsequently reported evidence of an interaction
between FLG loss-of-function mutations and water hardness
increasing AD risk, when studying high calcium concentra-
tions in water (> 256 mg L1 CaCO3) from 3 months of age
in this cohort (N = 1303; n = 75 with FLG null mutation
exposed to high CaCO3 levels, P = 0008).32
Vitamin D
A possible interaction between serum vitamin D levels and
FLG genotype was investigated by Berents et al. They measured
serum vitamin D levels in 558 participants at age 1–13
months and 2 years alongside interviews assessing vitamin D
intake. They did not find any evidence for an interaction (P >
013).33
Urine phthalate metabolites and household dust
phthalate
Phthalates are added to plastic to increase flexibility. They have
been reported to be associated with childhood AD.34 Wang
and Karmaus investigated whether there was an interaction
between urine phthalate metabolite levels and FLG genotype in
children aged 3 years in the aetiology of AD (n = 453). They
studied four phthalates, monoethyl phthalate, monobutyl
phthalate (MBP), monobenzyl pthathlate (MBzP) and mono(2-
ethyl-5-hydroxyhexyl) phthalate, which they classified as
lower or higher levels in relation to the median. They
reported evidence for an interaction between the P478S geno-
type TT and phthalates MBP (P = 0015) and MBzP (P =
0018)35 and increased AD risk; however, they did not repli-
cate their findings or perform corrections for multiple test-
ing.35 A similar interaction was investigated by Ait Bamai et al.
who assessed seven phthalates found in household dust, and
11 phosphorus flame retardants. They found evidence for an
interaction between FLG loss-of-functions and diisononyl
phthalate (P = 0039).36 The group also reported a nonsignifi-
cant negative dose–response relationship among children with
FLG loss-of-function mutation(s) in a categorical model (first
quartile compared with fourth quartile, P for trend = 0087).
This analysis was undertaken on a sample size of five children
with AD and FLG null genotypes and the researchers did not
correct for multiple testing.36
Quality of studies
Most studies included unselected cases from the general popu-
lation or cohorts, and controls were selected from the same
population as those with AD. FLG genotype was assessed using
accepted methodology (Table S3; see Supporting Information).
The timing and method of assessment of environmental expo-
sures was variable; studies may be vulnerable to reverse
causality owing to exposure status being assessed after AD
onset. Participants in each study were of homogeneous ethnic-
ity and analyses were adjusted for age. Details of confounder
adjustment were missing in five of 12 included studies
(Table S3; see Supporting Information). Studies varied in their
presentation of interaction results, with some providing only a
P-value or statement of statistical significance and others also
providing effect estimates and CIs across strata and a P-value
for the interaction term or statement of statistical significance
(Table S4; see Supporting Information). None of the included
studies adjusted for multiple testing and only Berents et al.
reported power calculations.33 The results of the studies sup-
ported their conclusions; however, they were underpowered
and therefore the results of these studies must be interpreted
with caution. Under reasonable assumptions on the magnitude
of main effects, prevalence of AD, environmental exposure
and SNP allele frequency, post hoc power calculations
(Table S2; see Supporting Information) indicate that the sam-
ple size required to detect an interaction with OR ~20 is
approximately 5000 individuals, whereas a sample size of
approximately 63 000 individuals is required to detect a more
modest GEI effect with OR 12.
Discussion
Our results highlight important challenges when studying GEIs
in the aetiology of AD. We identified only 12 articles that
reported FLG–environment interactions in AD. Our initial
search strategy returned many results, but the majority were
© 2019 The Authors. British Journal of Dermatology
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excluded because they lacked information essential to the
review. Evidence was found for interactions between FLG
genotype and breastfeeding duration, older siblings, phthalate
exposure in household dust and urine phthalate metabolite
levels, early-life exposure to cats, and water hardness. All
interactions increased the risk of AD apart from prolonged
breastfeeding, which decreased the risk. Owing to very limited
evidence in support of these interactions, small numbers and
lack of replication (one study undertook replication) it is diffi-
cult to interpret the results, and findings must be interpreted
with caution. Table 2 shows our suggestions of the compo-
nents required for a rigorous GEI study, which may improve
conclusions in future studies.
Our review has several strengths. A detailed search strategy
was used to identify all relevant papers. Screening and data
extraction were carried out in duplicate, with secondary reso-
lution of conflicts, reducing the possibility of introducing bias
by systematically selecting certain papers. The majority (10 of
12, 83%) of studies used data from cohort studies, thus they
were able to consider temporality, and researchers mostly
measured the outcome ‘AD’ using validated criteria.
Our findings should be considered in light of some limita-
tions. Many studies were excluded from the review as they
did not specifically test for GEI in their analyses. Studies were
also excluded if they measured indirect outcomes of AD by
examining IgE levels, transepidermal water loss, or skin-prick
tests, which are not measures of the outcome (AD), but
responses to exposures. Many of the included studies per-
formed GEI analysis as a secondary analysis, e.g. Berents
et al.,33 meaning they did not aim to have sufficient power to
assess GEIs; hence, the importance of measuring GEIs as pri-
mary outcome (Table 2). We were unable to evaluate the risk
of reporting biases formally, so we cannot rule out the possi-
bility that studies which found nonsignificant interactions yet
failed to report such results are missing from our review.
Many of the studies included in this review relied on popula-
tion data and there may be heterogeneity in outcome defini-
tion (Table 2).38 The predefined scope of this review was to
investigate FLG–environment interactions, which by definition
excluded the study of effects within populations where FLG
null mutations are not prevalent or have not been identi-
fied.7,39 Many large genetic studies have been conducted
within populations of European ancestry, where FLG null
mutations are prevalent. Ongoing work to increase diversity in
genetic research40 will allow future investigations of GEI in
populations of all ethnicities (Table 2).
Heterogeneity in methodology between published studies
and the limited number of studies assessing the same exposure
precluded meta-analysis or formal assessment of publication
bias. None of the included studies reported correcting for
multiple testing; hence, interaction effects could be a result of
chance. It is unclear how many studies had predefined
hypotheses, which risks introducing reporting bias. Replication
of findings was limited and in some cases where two studies
investigated the same interaction, discordant findings were
seen, such as Ziyab et al. (FLG genotype and breastfeeding)
and Henderson et al.28,30
One reason for the limited evidence for GEI and lack of
replication is lack of statistical power. Detailed review showed
that the number of individuals on which the interaction analy-
sis was based (i.e. cases with both exposure and FLG null
genotype) was small; hence, included studies were likely to
be underpowered. The number of individuals with both a FLG
loss-of-function mutation and exposure to the specific envi-
ronmental factor was not always specified, but in those studies
that did specify this number, it ranged from N = 5 to N =
167.24,28
In complex diseases such as AD, where the main genetic
effect sizes are small, a large sample size is necessary to detect
small interaction effects.41 Researchers need to utilize suffi-
ciently large sample sizes to detect GEIs, and generally investi-
gators should demonstrate that their sample has adequate
power to detect an interaction effect.42 Even in cases where
meta-analysis across studies is possible, results are not always
meaningful owing to variable measurement of environmental
exposures.41
Table 2 Components required for rigorous gene–environment
interaction (GEI) study
Suggestion Reason
Large sample size with
mutation and
environmental
exposure (Table S2; see
Supporting Information)
Sample size must be large
enough to detect true gene
by environment interaction
effect
Design the study basing the
sample size on power to
detect interaction effect
Design the study and basing
the sample size on power to
detect a main effect will likely
result in insufficient sample size
Use accepted diagnostic
criteria for atopic
dermatitis
This reduces the possibility of
introducing heterogeneity
into the results
Use robust methods of
exposure measurement
Questionnaires or indirect
measurements of exposure can
introduce variation and recall
bias into the results. Using
validated tools will help
reproducibility and reduce
information bias
Collect measurements of
exposure at defined time
periods across the study
population
This avoids variation in the
timing of exposure
measurements
influencing disease risk
Correct for multiple testing
and publication bias
This reduces the possibility of
interpreting chance results as
positive findings
Tailor studies to different
ethnic groups currently
not covered by research
Increasing diversity in genetic
research will enable us to
understand the importance
of GEIs in populations of
different ethnicities
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Studies of GEI face inherent challenges in attempting to gain
a full understanding of interactions because of the difficulty in
uniformly measuring the environmental parameter, which in
turn limits the understanding of the underlying disease mech-
anism.43 The difficulty in measuring exposure in GEI studies
in AD is shown in the Wang et al. study, which tested for an
interaction between phthalate exposure and FLG genotype. To
measure exposure, phthalate metabolite levels were measured
using urine samples.36 This is not a direct measure of the
exposure; therefore, we questioned whether it should be
included in the review. It provides only a moderate prediction
of exposure owing to the short half-life and rapid excretion of
phthalates leading to considerable day-to-day variation.36
Other studies used different methods, such as questionnaires,
to derive environmental exposure data retrospectively; this
could introduce recall bias.27
Variation in the timing of environmental exposure is impor-
tant in terms of influencing subsequent disease risk, as timing
of exposure may not be accurately measured with methods
such as infrequent questionnaires.44 Using robust validated
measures of exposure reduces variation and aids reproducibil-
ity of results (Table 2). For some of these exposures it is easy
to hypothesize a biological explanation as to why people with
FLG haploinsufficiency might have different responses; for
example, pet exposure and older siblings could act via micro-
bial exposure, as proposed by the hygiene hypothesis.45 With
other possible interactions such as urine phthalate metabolites,
it is harder to hypothesize plausible mechanisms. Cohort stud-
ies may be vulnerable to reverse causality when assessing
early-life exposures, as, although outcomes were measured
after the exposure in the majority of studies, there remains a
possibility that early signs of AD, or the presence of older sib-
lings with AD, influenced the behaviour of parents who subse-
quently modified the exposure.
GEIs are widely viewed as important in the aetiology of AD.
However, the limited evidence and lack of power of published
studies to detect GEI effects, as indicated by the sample-size
calculations we carried out, highlights the importance of fur-
ther research. Such research is needed to test for replication of
interactions reported to date (Table 1) using larger sample
sizes. Furthermore, unexplored GEIs may also warrant investi-
gation, including genetic risk variants in addition to FLG loss-
of-function mutations. The Early Genetics and Lifecourse Epi-
demiology consortium is investigating possible GEIs with
selected SNPs associated with AD. Our recommendations for
future studies of GEIs can be shown in Table 2, which would
improve the quality of evidence and enable us to draw more
robust conclusions about the nature of GEIs. Together this
work will improve understanding of GEI in the aetiology of
AD, which will help to inform both public health and individ-
ual lifestyle decisions.
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